Related references
Note: Only part of the references are listed.Bypassing anti-PD-(L)1 therapy: Mechanisms and management strategies
Keywan Mortezaee et al.
BIOMEDICINE & PHARMACOTHERAPY (2023)
Transition to invasive breast cancer is associated with progressive changes in the structure and composition of tumor stroma
Tyler Risom et al.
CELL (2022)
Tryptophan-derived microbial metabolites activate the aryl hydrocarbon receptor in tumor-associated macrophages to suppress anti-tumor immunity
Kebria Hezaveh et al.
IMMUNITY (2022)
Development and validation of a prognostic and predictive 32-gene signature for gastric cancer
Jae-Ho Cheong et al.
NATURE COMMUNICATIONS (2022)
Re-engineered BCG overexpressing cyclic di-AMP augments trained immunity and exhibits improved efficacy against bladder cancer
Alok Kumar Singh et al.
NATURE COMMUNICATIONS (2022)
Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses
Kunle Odunsi et al.
SCIENCE TRANSLATIONAL MEDICINE (2022)
Multifunctional metal-organic framework-based nanoreactor for starvation/oxidation improved indoleamine 2,3-dioxygenase-blockade tumor immunotherapy
Liangliang Dai et al.
NATURE COMMUNICATIONS (2022)
A pan-cancer metabolic atlas of the tumor microenvironment
Neha Rohatgi et al.
CELL REPORTS (2022)
Checkpoint inhibitor/interleukin-based combination therapy of cancer
Keywan Mortezaee et al.
CANCER MEDICINE (2022)
Immunogenomic landscape analyses of immune molecule signature-based risk panel for patients with triple-negative breast cancer
Cun Liu et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2022)
VISTA immune regulatory effects in bypassing cancer immunotherapy: Updated
Keywan Mortezaee et al.
LIFE SCIENCES (2022)
Anti-TGF-beta/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer
Ming Yi et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapy
Elnaz Rouzbahani et al.
BIOMEDICINE & PHARMACOTHERAPY (2022)
Extracellular vesicle-based checkpoint regulation and immune state in cancer
Keywan Mortezaee et al.
MEDICAL ONCOLOGY (2022)
Comprehensive assessment of multiple tryptophan metabolites as potential biomarkers for immune checkpoint inhibitors in patients with non-small cell lung cancer
M. Karayama et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2021)
Redox tolerance and metabolic reprogramming in solid tumors
Keywan Mortezaee
CELL BIOLOGY INTERNATIONAL (2021)
IL-2 regulates tumor-reactive CD8+ T cell exhaustion by activating the aryl hydrocarbon receptor
Yuying Liu et al.
NATURE IMMUNOLOGY (2021)
Inhibition of the BTK-IDO-mTOR axis promotes differentiation of monocyte-lineage dendritic cells and enhances anti-tumor T cell immunity
Madhav D. Sharma et al.
IMMUNITY (2021)
Inhibition of indoleamine 2,3-dioxygenase 1 synergizes with oxaliplatin for efficient colorectal cancer therapy
Xiaofei Miao et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2021)
Bifidobacterium bifidum strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice
Se-Hoon Lee et al.
NATURE MICROBIOLOGY (2021)
A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
Julie Westerlin Kjeldsen et al.
NATURE MEDICINE (2021)
The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1
Ming Yi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Protein phosphatase 2A inactivation induces microsatellite instability, neoantigen production and immune response
Yu-Ting Yen et al.
NATURE COMMUNICATIONS (2021)
Immune-regulated IDO1-dependent tryptophan metabolism is source of one-carbon units for pancreatic cancer and stellate cells
Alice Clare Newman et al.
MOLECULAR CELL (2021)
Pharmacological Wnt ligand inhibition overcomes key tumor-mediated resistance pathways to anti-PD-1 immunotherapy
Nicholas C. DeVito et al.
CELL REPORTS (2021)
Normalization in tumor ecosystem: Opportunities and challenges
Keywan Mortezaee
CELL BIOLOGY INTERNATIONAL (2021)
Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease
Kevin Mulder et al.
IMMUNITY (2021)
The current knowledge concerning solid cancer and therapy
Masoud Najafi et al.
JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY (2021)
The relationship between expression of PD-L1 and HIF-1α in glioma cells under hypoxia
Xing-chen Ding et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Myeloid-derived suppressor cells in cancer immunotherapy-clinical perspectives
Keywan Mortezaee
LIFE SCIENCES (2021)
Metabolic perturbations sensitize triple-negative breast cancers to apoptosis induced by BH3 mimetics
Veerle W. Daniels et al.
SCIENCE SIGNALING (2021)
The kynurenine pathway in chronic diseases: a compensatory mechanism or a driving force?
Niklas Joisten et al.
TRENDS IN MOLECULAR MEDICINE (2021)
Profiling the inhibitory receptors LAG-3, TIM-3, and TIGIT in renal cell carcinoma reveals malignancy
Kimiharu Takamatsu et al.
NATURE COMMUNICATIONS (2021)
Tumor-associated hematopoietic stem and progenitor cells positively linked to glioblastoma progression
I-Na Lu et al.
NATURE COMMUNICATIONS (2021)
Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas
Mirco Friedrich et al.
NATURE CANCER (2021)
Combination of EP4 antagonist MF-766 and anti-PD-1 promotes anti-tumor efficacy by modulating both lymphocytes and myeloid cells
Yun Wang et al.
ONCOIMMUNOLOGY (2021)
Decoding the multicellular ecosystem of lung adenocarcinoma manifested as pulmonary subsolid nodules by single-cell RNA sequencing
Xudong Xing et al.
SCIENCE ADVANCES (2021)
High Stromal TGFBI in Lung Cancer and Intratumoral CD8-Positive T Cells were Associated with Poor Prognosis and Therapeutic Resistance to Immune Checkpoint Inhibitors
Nobuhiro Nakazawa et al.
ANNALS OF SURGICAL ONCOLOGY (2020)
Resveratrol as an Adjuvant for Normal Tissues Protection and Tumor Sensitization
Keywan Mortezaee et al.
CURRENT CANCER DRUG TARGETS (2020)
Modularly Designed Peptide Nanoprodrug Augments Antitumor Immunity of PD-L1 Checkpoint Blockade by Targeting Indoleamine 2,3-Dioxygenase
Xuexiang Han et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2020)
Peptide vaccination directed against IDO1-expressing immune cells elicits CD8+and CD4+T-cell-mediated antitumor immunity and enhanced anti-PD1 responses
Souvik Dey et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine
Luis Felipe Campesato et al.
NATURE COMMUNICATIONS (2020)
The role of curcumin/curcuminoids during gastric cancer chemotherapy: A systematic review of non-clinical study
Masoud Najafi et al.
LIFE SCIENCES (2020)
Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy
Yang Gao et al.
NATURE CELL BIOLOGY (2020)
Breast cancer-associated macrophages promote tumorigenesis by suppressing succinate dehydrogenase in tumor cells
Valenti Gomez et al.
SCIENCE SIGNALING (2020)
Aryl hydrocarbon receptor ligand production by the gut microbiota is decreased in celiac disease leading to intestinal inflammation
Bruno Lamas et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Anti-tumour immunity induces aberrant peptide presentation in melanoma
Osnat Bartok et al.
NATURE (2020)
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
Kyung Hae Jung et al.
CLINICAL CANCER RESEARCH (2019)
The landscape of cancer cell line metabolism
Haoxin Li et al.
NATURE MEDICINE (2019)
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
Georgina Long et al.
LANCET ONCOLOGY (2019)
Identification of BAY-218, a potent and selective small-molecule AhR inhibitor, as a new modality to counteract tumor immunosuppression
Norbert Schmees et al.
CANCER RESEARCH (2019)
In vivo inhibition of tryptophan catabolism reorganizes the tuberculoma and augments immune-mediated control of Mycobacterium tuberculosis
Uma S. Gautam et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Bertrand Routy et al.
SCIENCE (2018)
Tumor-Repopulating Cells Induce PD-1 Expression in CD8(+) T Cells by Transferring Kynurenine and AhR Activation
Yuying Liu et al.
CANCER CELL (2018)
Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme
Todd A. Triplett et al.
NATURE BIOTECHNOLOGY (2018)
Genetic deficiency of indoleamine 2,3-dioxygenase promotes gut microbiota-mediated metabolic health
Ludivine Laurans et al.
NATURE MEDICINE (2018)
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Vyara Matson et al.
SCIENCE (2018)
A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma
Lukas Krahenbuhl et al.
NEOPLASIA (2018)
Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles
Franz L. Ricklefs et al.
SCIENCE ADVANCES (2018)
Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors
Asha Nayak-Kapoor et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)
Tara C. Mitchell et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Epacadostat plus nivolumab for advanced melanoma: Updated phase 2 results of the ECHO-204 study
Adil Daud et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Epacadostat plus pembrolizumab in patients with advanced melanoma and select solid tumors: Updated phase 1 results from ECHO-202/KEYNOTE-037
T.C. Gangadhar et al.
ANNALS OF ONCOLOGY (2017)
A Relay Pathway between Arginine and Tryptophan Metabolism Confers Immunosuppressive Properties on Dendritic Cells
Giada Mondanelli et al.
IMMUNITY (2017)
Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients
Hojabr Kakavand et al.
MODERN PATHOLOGY (2017)
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
Jianjun Gao et al.
NATURE MEDICINE (2017)
INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (ID01) Inhibitor for Immunooncology
Eddy W. Yue et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
Structural insights into substrate and inhibitor binding sites in human indoleamine 2,3-dioxygenase 1
Ariel Lewis-Ballester et al.
NATURE COMMUNICATIONS (2017)
Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression
Jianqin Lu et al.
NATURE COMMUNICATIONS (2017)
Prostaglandin E2 and PD-1 mediated inhibition of antitumor CTL responses in the human tumor microenvironment
Jie Miao et al.
ONCOTARGET (2017)
Combination immunotherapy with IDO vaccine and PD-1 inhibitors in advanced NSCLC.
Anders Mellemgaard et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A phase Ib dose escalation study of combined inhibition of IDO1 (GDC-0919) and PD-L1 (atezolizumab) in patients (pts) with locally advanced or metastatic solid tumors
Howard A. Burris et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Interim analysis of the Phase 2 clinical trial of the IDO pathway inhibitor indoximod in combination with pembrolizumab for patients with advanced melanoma
Yousef Zakharia et al.
CANCER RESEARCH (2017)
BMS-986205, an optimized indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, is well tolerated with potent pharmacodynamic (PD) activity, alone and in combination with nivolumab (nivo) in advanced cancers in a phase 1/2a trial
Lillian L. Siu et al.
CANCER RESEARCH (2017)
First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies
Gregory L. Beatty et al.
CLINICAL CANCER RESEARCH (2017)
Epacadostat plus pembrolizumab in patients with advanced RCC: Preliminary phase I/II results from ECHO-202/KEYNOTE-037.
Primo Lara et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
The aryl hydrocarbon receptor links integrin signaling to the TGF-β pathway
M. Silginer et al.
ONCOGENE (2016)
Updated results from a phase 1/2 study of epacadostat (INCB024360) in combination with ipilimumab in patients with metastatic melanoma
G. Gibney et al.
EUROPEAN JOURNAL OF CANCER (2015)
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Marie Vetizou et al.
SCIENCE (2015)
PGE2-Induced IDO1 Inhibits the Capacity of Fully Mature DCs to Elicit an In Vitro Antileukemic Immune Response
Sara Trabanelli et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2015)
The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment
Madhav D. Sharma et al.
SCIENCE ADVANCES (2015)
PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials
Jason Madore et al.
PIGMENT CELL & MELANOMA RESEARCH (2015)
Peritumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control?
I. Chevolet et al.
BRITISH JOURNAL OF DERMATOLOGY (2014)
Synergistic antitumor effects of combinatorial immune checkpoint inhibition with anti-PD-1/PD-L antibodies and the IDO pathway inhibitors NLG-919 and indoximod in the context of active immunotherapy
Mario R. Mautino et al.
CANCER RESEARCH (2014)
Diet rapidly and reproducibly alters the human gut microbiome
Lawrence A. David et al.
NATURE (2014)
Aryl hydrocarbon receptor control of a disease tolerance defence pathway
Alban Bessede et al.
NATURE (2014)
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment
Stefani Spranger et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Resveratrol suppresses tumor progression via the regulation of indoleamine 2,3-dioxygenase
Kyung Tae Noh et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2013)
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
Rikke B. Holmgaard et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
Stefani Spranger et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
Seng-Ryong Woo et al.
CANCER RESEARCH (2012)
Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients
Reinhart Speeckaert et al.
EUROPEAN JOURNAL OF CANCER (2012)
Activated CD69+ T Cells Foster Immune Privilege by Regulating IDO Expression in Tumor-Associated Macrophages
Qiyi Zhao et al.
JOURNAL OF IMMUNOLOGY (2012)
Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells
Maria T. Pallotta et al.
NATURE IMMUNOLOGY (2011)
Curcumin Suppresses the Induction of Indoleamine 2,3-Dioxygenase by Blocking the Janus-activated Kinase-Protein Kinase Cδ-STAT1 Signaling Pathway in Interferon-γ-stimulated Murine Dendritic Cells
Young-Il Jeong et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Aryl hydrocarbon receptor inhibition downregulates the TGF-β/Smad pathway in human glioblastoma cells
D. Gramatzki et al.
ONCOGENE (2009)
CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition
Michael S. von Bergwelt-Baildon et al.
BLOOD (2006)
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
E Sato et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase
DH Munn et al.
IMMUNITY (2005)
Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy
AJ Muller et al.
NATURE MEDICINE (2005)
Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells
DH Munn et al.
JOURNAL OF IMMUNOLOGY (2004)
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
C Uyttenhove et al.
NATURE MEDICINE (2003)
CTLA-4-Ig regulates tryptophan catabolism in vivo
U Grohmann et al.
NATURE IMMUNOLOGY (2002)
T cell apoptosis by tryptophan catabolism
I Fallarino et al.
CELL DEATH AND DIFFERENTIATION (2002)
Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells:: Mediation of suppression by tryptophan metabolites
P Terness et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)